These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20158400)

  • 1. Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.
    Llibre JM; Schapiro JM; Clotet B
    Clin Infect Dis; 2010 Mar; 50(6):872-81. PubMed ID: 20158400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
    De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G
    Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging resistance profiles of newly approved antiretroviral drugs.
    Daar ES
    Top HIV Med; 2008; 16(4):110-6. PubMed ID: 18838744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice.
    Imaz A; Falcó V; Ribera E
    AIDS Rev; 2011; 13(3):180-93. PubMed ID: 21799536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
    Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
    Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D;
    Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic resistance mutations in treatment-naïve and treatment-experienced patients under widespread use of antiretroviral drugs in Thailand: implications for further epidemiologic surveillance.
    Sukasem C; Churdboonchart V; Sirisidthi K; Riengrojpitak S; Chasombat S; Watitpun C; Piroj W; Tiensuwan M; Chantratita W
    Jpn J Infect Dis; 2007 Sep; 60(5):284-9. PubMed ID: 17881868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
    Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
    J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational agents for salvage.
    Pozniak AL
    Curr Opin HIV AIDS; 2009 Nov; 4(6):524-30. PubMed ID: 20048721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of antiretroviral resistance on response in treatment-experienced patients.
    Kuritzkes DR
    AIDS Read; 2003 Dec; 13(12 Suppl Antiretroviral):S5-11. PubMed ID: 19967805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.
    Hughes CA; Robinson L; Tseng A; MacArthur RD
    Expert Opin Pharmacother; 2009 Oct; 10(15):2445-66. PubMed ID: 19678794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral drug resistance and resistance testing.
    Gallant JE
    Top HIV Med; 2005 Dec-2006 Jan; 13(5):138-42. PubMed ID: 16377851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
    Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An algorithm-based genotypic resistance score is associated with clinical outcome in HIV-1-infected adults on antiretroviral therapy.
    Ormaasen V; Sandvik L; Asjø B; Holberg-Petersen M; Gaarder PI; Bruun JN
    HIV Med; 2004 Nov; 5(6):400-6. PubMed ID: 15544691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A virological perspective on resistance in highly treatment-experienced patients.
    Geretti AM
    J HIV Ther; 2002 Nov; 7(4):97-101. PubMed ID: 12733608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.
    Cardoso LP; Queiroz BB; Stefani MM
    J Clin Virol; 2009 Oct; 46(2):134-9. PubMed ID: 19682948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure.
    Montroni M; Monforte AD
    Scand J Infect Dis Suppl; 2003; 106():79-81. PubMed ID: 15000591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
    Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
    J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of earlier HIV-1 drug resistance mutations at new treatment failure.
    Svedhem V; Lindkvist A; Lidman K; Sönnerborg A
    J Med Virol; 2002 Dec; 68(4):473-8. PubMed ID: 12376953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.